Abstract:By introducing double heavy‐atoms of Se and Br, a new type‐I photosensitizer of Se6 have been designed and exhibit high efficiencies of generating radicals of both O2• ̅ and •OH upon irradiation. This provides a switch‐hitter of dual‐radical with complementary lifetimes for outstanding photodynamic therapy in hypoxia, leading to significant anticancer outcome with tumor growth inhibition rates of 99%. Organic type‐I photosensitizers (PSs) which produce aggressive reactive oxygen species (ROS) with less oxygen‐dependent exhibit attractive curative effect for photodynamic therapy (PDT), as they adapt better to hypoxia microenvironment in tumors. However, the reported type‐I PSs are limited and its exacted mechanism of oxygen dependence is still unclear. Herein, new selenium‐containing type‐I PSs of Se6 and Se5 with benzoselenadiazole acceptor has been designed and possessed aggregation‐induced emission characteristic. Benefited from double heavy‐atom‐effect of selenium and bromine, Se6 shows a smaller energy gap (ΔEST) of 0.03 eV and improves ROS efficiency. Interestingly, type‐I radicals of both long‐lived superoxide anion (O2• ̅) and short‐lived hydroxyl (•OH) are generated from them upon irradiation. This may provide a switch‐hitter of dual‐radical with complementary lifetimes for PDT. More importantly, simultaneous processes to produce •OH are revealed, including disproportionation of O2• ̅ and reaction between excited PS and water. Actually, Se6 displays superior in–vitro PDT performance to commercial chlorin e6 (Ce6), under normoxia or hypoxia. After intravenous injection, a significantly in–vivo PDT performance is demonstrated on Se6, where tumor growth inhibition rates of 99% is higher than Ce6. These findings offer new insights about both molecular design and mechanism study of type‐I PSs.

Asymmetric A‐DA′D‐A′′ Molecular Configuration Type‐I Photosensitizer with Two Complementary Reactive Oxygen Species for Efficient Imaging and Photodynamic Therapy

Type-I organic photosensitizers with two complementary reactive oxygen species based on donor-acceptor (D-A) molecules

Efficient type I and type II ROS generated aggregation-induced emission photosensitizer for mitochondria targeted photodynamic therapy

Amplifying Free Radical Generation of AIE Photosensitizer with Small Singlet–Triplet Splitting for Hypoxia-Overcoming Photodynamic Therapy

An E/Z isomer strategy of photosensitizers with tunable generation processes of reactive oxygen species

A E/Z Isomers Strategy of Photosensitizers with Tunable Generation Processes of Reactive Oxygen Species

Optimizing Photosensitizers with Type I and Type II ROS Generation Through Modulating Triplet Lifetime and Intersystem Crossing Efficiency

An Acceptor-Shielding Strategy of Photosensitizers for Enhancing the Generation Efficiency of Type I Reactive Oxygen Species and the Related Photodynamic Immunotherapy

Mechanism research of type I reactive oxygen species conversion based on molecular and aggregate levels for tumor photodynamic therapy

Selenium‐Containing Type‐I Organic Photosensitizers with Dual Reactive Oxygen Species of Superoxide and Hydroxyl Radicals as Switch‐Hitter for Photodynamic Therapy

A Facile Supramolecular Strategy to Switch Photodynamic Pathway and Augment ROS Production of Sensitizers for Enhanced Tumor Therapy

Rational design of type-I photosensitizer molecules for mitochondrion-targeted photodynamic therapy

An AIE-active type I photosensitizer based on N,N′-diphenyl-dihydrophenazine for high-performance photodynamic therapy under hypoxia

Type I Photosensitization with Strong Hydroxyl Radical Generation in NIR Dye Boosted by Vigorous Intramolecular Motions for Synergistic Therapy

Unusual Electron Donor-Acceptor Sequenced NIR AIEgen for Highly Efficient Mitochondria-Targeted Cancer Cell Photodynamic Therapy.

An AIE Photosensitizer with Simultaneous Type I and Type II ROS Generation: Efficient Bacterial Elimination and Hypoxic Tumor Ablation

A Feasible Strategy of Fabricating Type I Photosensitizer for Photodynamic Therapy in Cancer Cells and Pathogens

Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy.

Building Block for Designing Bright Type I AIE‐Active Photosensitizers with Deep/Near‐infrared Red Fluorescence

Oxygen-independent Organic Photosensitizer with Ultralow-Power NIR Photoexcitation for Tumor-Specific Photodynamic Therapy

Oxidization enhances type I ROS generation of AIE-active zwitterionic photosensitizers for photodynamic killing of drug-resistant bacteria